U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H7N2O5.Na
Molecular Weight 330.2269
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIRENOXINE SODIUM

SMILES

[Na+].OC1=CC(=NC2=C1C3=NC4=CC=CC=C4OC3=CC2=O)C([O-])=O

InChI

InChIKey=HDQXPMXHXZNPKE-UHFFFAOYSA-M
InChI=1S/C16H8N2O5.Na/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12;/h1-6H,(H,18,19)(H,21,22);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H7N2O5
Molecular Weight 307.2372
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including, http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02021053&Seq=007&Type=9

Pirenoxine is an anti-cataract agent which is used in many asian countries under the name Catalin. Although its efficacy is not proved scientifically, the drug may play an important role in cataract prevention. It is supposed that the anti-cataract effect of pirenoxine results from inhibition of sulfhydryl combination of quinoid substances with lens proteins and the inhibition leads to the maintenance of lens transparency.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CATALIN

Approved Use

Early stage of senile cataract.
PubMed

PubMed

TitleDatePubMed
Antioxidant protection in cultured corneal cells and whole corneas submitted to UV-B exposure.
2003 Oct 15
[Evaluation of effectiveness of Catalin eyedrops in patients with presenile and senile cataract].
2004
Contact dermatitis due to pirfenoxone.
2004 Jun
Pirenoxine prevents oxidative effects of argon fluoride excimer laser irradiation in rabbit corneas: biochemical, histological and cytofluorimetric evaluations.
2005 Jan 14
Why are physicians not persuaded by scientific evidence? A grounded theory interview study.
2006 Jul 27
[Efficacy of catalin eyed drops in age-related cataract agents].
2010 Jan-Feb
Patents

Patents

Sample Use Guides

Dissolve the granules (0.75 mg) in 15 ml of the vehicle just before use and instill 1-2 drops of the solution, 3-5 times a day
Route of Administration: Other
In Vitro Use Guide
Pirenoxine (1,000 uM) decreased UVC-induced turbidity formation compared to controls after 4 h of UVC exposure. The absolute gamma-crystallin turbidity induced by 4 h of UVC exposure was ameliorated in the presence of catalin equivalent to 1-100 uM of the drug in a concentration-dependent manner. Pirenoxine at 0.03, 0.1, and 0.3 uM significantly delayed 10 mM selenite- and calcium-induced turbidity formation compared to controls on days 0-4.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:46:02 GMT 2023
Edited
by admin
on Fri Dec 15 18:46:02 GMT 2023
Record UNII
95JU7URF64
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIRENOXINE SODIUM
MART.   WHO-DD  
Common Name English
5H-PYRIDO(3,2-A)PHENOXAZINE-3-CARBOXYLIC ACID, 1-HYDROXY-5-OXO-, MONOSODIUM SALT
Common Name English
PIRENOXINE SODIUM SALT
MI  
Common Name English
CATALIN SODIUM
Common Name English
SODIUM 1-HYDROXY-5-OXO-5H-PYRIDO(3,2-A)(PHENOXAZINE-3-CARBOXYLATE
Common Name English
PIRENOXINE SODIUM SALT [MI]
Common Name English
5H-PYRIDO(3,2-A)PHENOXAZINE-3-CARBOXYLIC ACID, 1-HYDROXY-5-OXO-, SODIUM SALT (1:1)
Common Name English
PIRFENOXONE SODIUM
Common Name English
Pirenoxine sodium [WHO-DD]
Common Name English
PIRFENOXONE SODIUM SALT
Common Name English
PIRENOXINE SODIUM [MART.]
Common Name English
Code System Code Type Description
PUBCHEM
23695982
Created by admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID1046637
Created by admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
PRIMARY
ECHA (EC/EINECS)
257-181-6
Created by admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
PRIMARY
EVMPD
SUB20995
Created by admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
PRIMARY
SMS_ID
100000087311
Created by admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
PRIMARY
MERCK INDEX
m8873
Created by admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
PRIMARY Merck Index
CAS
51410-30-1
Created by admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
PRIMARY
FDA UNII
95JU7URF64
Created by admin on Fri Dec 15 18:46:02 GMT 2023 , Edited by admin on Fri Dec 15 18:46:02 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY